Posts tagged as: biotechnology investing back to homepage
 |
FDA Responds to Ventrus Biosciences on New Anal Fissure Drug(0) Ventrus Biosciences, Inc. (NASDAQ: VTUS) said Monday that, based upon written communication with the FDA, they anticipate filing a new drug application for VEN 307 (diltiazem hydrochloride cream, a calcium channel blocker) as a new therapeutic for anal fissures upon completion of a second Phase 3 study. The New York City-based biotech specializing in gastrointestinal products has begun enrollment for the clinical trial and expects results early in the fourth quarter of Read More |
 |
Cellceutix Selects Dr. Reddy’s for Manufacturing of New Psoriasis Drug(0) Beverly, Massachusetts-based Cellceutix Corporation (OTCBB: CTIX) reported this morning that they have chosen Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) to synthesize and manufacture Prurisol, Cellceutix’s lead anti-psoriasis drug candidate. Cellceutix will be advancing Prurisol into Phase II/III clinical trials under guidance from the Food and Drug Administration that the drug qualifies for a 505(b)(2) designation. Read More |
 |
FDA Gives Nod to Cellceutix for 505(b)(2) Eligibility for Psoriasis Drug(0) Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, reports today that it has participated in a meeting with the U.S. Food and Drug Administration (“FDA”) pertaining to the Company’s psoriasis compound, Prurisol™. As previously disclosed on April 16, 2012, the Company had Read More |
|
Cellceutix to Meet with FDA on New Psoriasis Drug(0) This one day might be the story called “The Little Biotech That Could”. Cellceutix Corp. (OTCBB: CTIX) has a pipeline of eight drugs with three that have already begun clinical trials (one for cancer, one for psoriasis and one for autism). The flagship drug, Kevetrin™ is being developed as an anti-cancer drug with clinical trials slated to be hosted at the vaunted Dana-Farber Cancer Center. Read More |
 |
Cancer News: Cellceutix Updates Shareholders on Kevetrin™(0) Cellceutix Corporation (OTCQB:CTIX) provided shareholders with an update on the status of the Investigational New Drug filing for Kevetrin™, their lead compound as an indication for a variety of cancers. The Company has met with world-class cancer centers regarding hosting the clinical trials for Kevetrin™, a completely novel cancer therapy with strong pre-clinical data as a treatment for several strains of cancer including pancreatic, lung, breast and colon, and is now awaiting replies from the institutions. Read the full press release and get CTIX stock quote. Facebook page now open. Take a moment to Like us. |
OTCBB News
read more
Stay Informed
Dana-Farber to Host Cellceutix Trials
Diabetes Rate Growing Exponentially
According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.
